Kidney Diseases  >>  Inlyta (axitinib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Inlyta (axitinib) / Pfizer
NCT00076011: Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma

Completed
2
52
US, Europe
Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor
Pfizer
Kidney Neoplasms
02/07
02/07
NCT00282048: Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer

Completed
2
62
US
AG-013736 (axitinib)
Pfizer
Kidney Neoplasms, Carcinoma, Renal Cell
02/09
06/09
NCT00835978 / 2008-007786-23: Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark First line mRCC
Oct 2013 - Oct 2013: First line mRCC
Checkmark ESMO-ECCO-ESTRO 2013
More
Completed
2
213
Japan, US, Europe, RoW
axitinib
Pfizer
Carcinoma, Renal Cell
10/12
02/16
NCT01441414 / 2011-002190-33: PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Terminated
2
18
US, RoW
PF-04856884, Axitinib (AG-013736)
Pfizer
Metastatic Renal Cell Carcinoma
03/14
03/14

Download Options